The biotechnology industry in Australia is experiencing rapid growth and change as participants continue to develop new technologies and adapt business models to an evolving regulatory and competitive environment.
With continued developments in genomic and proteomic medicine, gene editing and engineering, biologics and biopharmaceuticals as well as in AI, big data and analytics, our team are helping clients with leading commercial and regulatory advice across the full range of issues they face.
We assist clients to take advantage of M&A opportunities in an active market.
Our advice includes:
- Patent, patent term extension and other intellectual property litigation
- Regulatory law
- Competition and anti-trust issues
- Licensing commercialisation and supply arrangements
- Commercial dispute resolution (including product liability, competition litigation and regulatory litigation)
- Marketing and advertising issues
- Brand clearance, protection, exploitation and enforcement
- Corporate advice (including fund formation, capital raising, corporate structures, joint ventures, tax, mergers and acquisitions, takeovers and de-mergers)
- Finance, advising both lenders and borrowers.
Our experience in biotechnology
- Avexa: advising the Australian based biotechnology and research development company in its merger with Progen Pharmaceuticals, subsequently creating one of the largest biopharmaceutical companies in Australia.
- Queensland Biocapital Fund: advising on various acquisitions, investment management and divestures.
- Telesso Technologies: advising the Australian-based biotechnology company on its acquisition of UATC business from Uniquest and investment in Telesso.
- Biota: advising Biota on its US$231 million contract with the United States’ Office of Biomedical Advanced Research and Development Authority (“BARDA”) for the development of an anti-viral drug.
- CSIRO: advising on a range of regulatory and commercial dealings, including in relation to the regulatory and contracting architecture for the BioFoundry robotic synthetic construction facility.
- The University of Queensland: advising on commercial agreements in relation to the development of a novel coronavirus vaccine and in relation to risk, liability and regulatory issues in relation to development of vaccines.
- Arcus Biosciences: advising on clinical trial regulation in Australia.
- Samsung Bioepis: advising in relation to the Australian aspects of a multi-jurisdictional series of patent disputes concerning patents for formulations for an antirheumatic drug.
- Sandoz: defending an action brought by Roche against Sandoz relating to patents for leading haematology drug, rituximab – this was the first case in Australia relating to the launch of a biosimilar.
